3,8-dimethylimidazo[1,2-a]pyridine | 1284210-50-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: 3,8-dimethylimidazo[1,2-a]pyridine
• 英文别名: 3,8-dimethylimidazo[1,2-α]pyridine
• CAS: 1284210-50-9
• 化学式: C₉H₁₀N₂
• 分子量: 146.192
• InChiKey: DFANMZKBEABQEH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  17.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  3-methyl-N-(prop-2-yn-1-yl)pyridin-2-amine 以 水 为溶剂， 反应 1.0h， 以80%的产率得到3,8-dimethylimidazo[1,2-a]pyridine
  参考文献：
  名称：

  Synthesis of Imidazo[1,2-a]pyridines: “Water-Mediated” Hydroamination and Silver-Catalyzed Aminooxygenation

  摘要：

  Aqueous syntheses of methylimidazo[1,2-a]pyridines without any deliberate addition of catalyst are reported. Imidazo[1,2-a]pyrazine and imidazo[2,1-a]isoquinoline were also obtained in good yields under similar conditions. With acetonitrile as solvent, Ag-catalyzed intra-molecular aminooxygenation produced imidazo[1,2-a]pyridine-3-carbaldehydes in moderate to good yields.

  DOI：

  10.1021/jo3025303

文献信息

• Heterocyclic Compounds As CCR1 Receptor Antagonists
  申请人：Cook Brian Nicholas

  公开号：US20120270879A1

  公开（公告）日：2012-10-25

  Disclosed are CCR1 receptor antagonists of the formula (I) wherein Ar1, Ar2, R1-R3, X and L are disclosed herein. Also disclosed are compositions, methods of making and using compounds of the formula (I).

  本发明涉及式(I)的CCR1受体拮抗剂，其中Ar1、Ar2、R1-R3、X和L在此披露。本发明还涉及式(I)化合物的组合物、制备方法和使用方法。
• AZAHETEROARYL COMPOUND AND APPLICATION THEREOF
  申请人：Blueray Therapeutics (Shanghai) Co., Ltd

  公开号：EP4019521A1

  公开（公告）日：2022-06-29

  Disclosed in the present disclosure are an azaheteroaryl compound, a pharmaceutically acceptable salt thereof, and a solvate thereof. The present disclosure also provides a method for preparing said compound, a composition containing said compound, and a use of said compound in the preparation of a drug for treating a disease or disorder related to the mechanism of action of an EED protein and/or a PRC2 protein complex. (Formula 1)

  本公开揭示了一种氮杂杂环化合物及其药学上可接受的盐和溶剂化物。本公开还提供了一种制备该化合物的方法、含有该化合物的组合物以及将该化合物用于制备用于治疗与EED蛋白和/或PRC2蛋白复合物作用机制相关的疾病或障碍的药物的用途。(式1)
• [EN] HPK1 ANTAGONISTS AND USES THEREOF<br/>[FR] ANTAGONISTES DE HPK1 ET LEURS UTILISATIONS
  申请人：NIMBUS SATURN INC

  公开号：WO2022174253A1

  公开（公告）日：2022-08-18

  The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.

  本发明提供了化合物、其组合物以及使用它们抑制HPK1和治疗HPK1介导的疾病的方法。
• TRIAZINE COMPOUND AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
  申请人：Shenzhen Forward Pharmaceuticals Co., Ltd.

  公开号：EP3705478A1

  公开（公告）日：2020-09-09

  The invention discloses a triazine derivative and a pharmaceutically acceptable salt, a pharmaceutical composition and use thereof. Particularly, the invention discloses a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3 and R4 are defined as described in the description and claims. The compound or a salt thereof according to the invention may be used for treating or preventing diseases or conditions by regulating some mutation forms of epidermal growth factor receptors. The invention also discloses a pharmaceutical composition comprising the compound or a salt thereof, and a method for treating various forms of EGFR-mediated diseases (including non-small cell lung cancer) by using the compound and a salt thereof.

  本发明公开了一种三嗪衍生物和一种药学上可接受的盐、一种药物组合物及其用途。特别是，本发明公开了式 (I) 的化合物或其药学上可接受的盐，其中 R1、R2、R3 和 R4 的定义如说明书和权利要求书中所述。根据本发明的化合物或其盐可用于通过调节表皮生长因子受体的某些突变形式来治疗或预防疾病或病症。本发明还公开了一种包含本发明化合物或其盐的药物组合物，以及一种通过使用本发明化合物及其盐治疗各种形式的表皮生长因子受体介导的疾病（包括非小细胞肺癌）的方法。
• [EN] AZAHETEROARYL COMPOUND AND APPLICATION THEREOF<br/>[FR] COMPOSÉ D'AZAHÉTÉROARYLE ET SON UTILISATION<br/>[ZH] 氮杂芳基化合物及其应用
  申请人：SHANGHAI BLUERAY BIOPHARMA CO LTD

  公开号：WO2021032004A1

  公开（公告）日：2021-02-25

  本发明公开了氮杂芳基化合物、其药学上可接受的盐及其溶剂化物。本发明也提供了该类化合物的制备方法、含有该类化合物的组合物以及该类化合物用于制备治疗与EED蛋白和/或PRC2蛋白复合物作用机理相关疾病或障碍的药物用途。（式1）